Stockscreener 앱 받기
256.91
0.94%
-2.45
시장 영업 전:
258.59
1.68
+0.65%
Abbvie Inc 주식(ABBV)의 최신 뉴스
Should You Buy AbbVie Stock Hand Over Fist Before July 31? - The Motley Fool
AbbVie Seeks Block On Alkem Generic Constipation Drug - Law360
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive
AbbVie Researcher Dr. Jan Stoehr Outlines Use of Biomarkers to Target Parkinson’s Disease Progression - geneonline.com
Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
AbbVie stock hits all-time high of 261.71 USD - Investing.com
Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet - TIKR.com
How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing - Stock Traders Daily
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio? - The Motley Fool
AbbVie Inc Agencies, 2026 - OpenSecrets
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? - The Motley Fool
AbbVie stock steadies as investors weigh Humira erosion against Skyrizi and Rinvoq growth - Ad-hoc-news.de
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback - Yahoo Finance
AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth - AD HOC NEWS
Should You Pay Attention To AbbVie Stock's Momentum? - Trefis
AbbVie stock may move 4.2% on July 31 earnings report By Investing.com - Investing.com Nigeria
AbbVie stock may move 4.2% on July 31 earnings report - Investing.com
AbbVie: A Dividend Fortress At An Appealing Price Tag - Seeking Alpha
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint - GuruFocus
AbbVie, Genmab post trial setback for lymphoma drug (ABBV:NYSE) - Seeking Alpha
CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras SystemsNetflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS - Benzinga
AbbVie stock trades steadily as investors weigh Skyrizi and Rinvoq growth against Humira erosion - AD HOC NEWS
ABBV|AbbVie Inc|Price:259.360|Chg%:+2.300 - TradingKey
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV) - The Globe and Mail
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint - Stock Titan
AbbVie: Bright Future, But Already Priced In (NYSE:ABBV) - Seeking Alpha
Donald TrumpABBVIE INC COM UNSOLICITED Trump Trade on Mar. 25, 2026 - Quiver Quantitative
AbbVie stock holds near record levels after second-quarter results - Ad-hoc-news.de
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Total equity of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs - Bloomberg Law News
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2? - TradingView
Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating - marketscreener.com
Canaccord raises Abbvie stock price target to $282 on growth outlook - Investing.com
ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana - GuruFocus
ETFs Investing in AbbVie, Inc. Stocks - TradingView
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin - Yahoo Finance
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
EBIT per share of AbbVie, Inc. – BCS:ABBVCL1 - TradingView
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Enterprise value of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Stock Zigs When The Market Zags - Trefis
AbbVie stock advances on a strong 2025 base - Ad-hoc-news.de
J&J, Eli Lilly, or AbbVie? How to Play Big Pharma in a Diverging Market - finance.biggo.com
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal - Endpoints News
AbbVie’s Allergan gets European nod for its Botox-lite treatment - Crain's Chicago Business
AbbVie Inc. (ABBV): Investor Outlook Highlights Robust Revenue Growth and Dividend Appeal - DirectorsTalk Interviews
A 54-Year Dividend Streak Meets a $10.9 Billion Acquisition: Here’s Why AbbVie’s Payouts Are Safe - NAI500
AbbVie stock holds firm as Humira biosimilar impact is offset by Skyrizi and Rinvoq growth - ad-hoc-news.de
0.24%
0.71%
자본화:
|
볼륨(24시간):